-
Neuropsychiatric Disease and Treatment
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer’s disease
Original Research
(2312) Views (482) Full article downloads
Authors: William J McGeown, Michael F Shanks, Annalena Venneri
Published Date April 2008
Volume 2008:4(2) Pages 465 - 476
DOI: http://dx.doi.org/10.2147/NDT.S2461
William J McGeown1, Michael F Shanks1, Annalena Venneri1,2
1University of Hull, Hull, UK; 2University of Modena and Reggio Emilia, Italy
Abstract: Neuroimaging studies of cholinesterase inhibitor (ChEI) treatment in Alzheimer’s disease (AD) indicate that the short and long term actions of ChEIs are dissimilar. fMRI studies of the ChEI rivastigmine have focused on its short term action. In this exploratory study the effect of prolonged (20 weeks) rivastigmine treatment on regional brain activity was measured with fMRI in patients with mild AD. Eleven patients with probable AD and nine age-matched controls were assessed with a Pyramids and Palm Trees semantic association and an n-back working memory fMRI paradigm. In the patient group only, the assessment was repeated after 20 weeks of treatment. There was an increase in task-related brain activity after treatment with activations more like those of normal healthy elderly. Behaviorally, however, there were no significant differences between baseline and retest scores, with a range of performance probably reflecting variation in drug efficacy across patients. Variable patient response and drug dynamic/kinetic factors in small patient groups will inevitably bias (either way) the effect size of any relevant drug related changes in activation. Future studies should take drug response into account to provide more insight into the benefits of ChEI drugs at the individual level.
Keywords: fMRI, rivastigmine, treatment, dementia, Alzheimer’s disease
Readers of this article also read:
Absence status associated with focal activity and polydipsia-induced hyponatremia
The development of behavioral and endocrine abnormalities in rats after repeated exposure to direct and indirect stress
The prognostic value of injury severity, location of event, and age at injury in pediatric traumatic head injuries
Role of phosphodiesterase 5 in synaptic plasticity and memory
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Corrigendum
Erratum
A case of recurrent bloody tears
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
- Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety
- Moderate alcohol consumption and cognitive risk
- Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference




